A recent study by researchers in France has shown that nivolumab may continue to benefit some people with advanced renal cell carcinoma (RCC) who have experienced disease progression while on the drug.

Researchers reported that 13% of patients who remained on nivolumab therapy after disease progression experienced a 30% or greater reduction in tumour burden. The study also showed that continued therapy with nivolumab has an acceptable safety profile.

Read more here